Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib

Xiaomei Ren, Xiaofen Pan, Zhang Zhang, Deping Wang, Xiaoyun Lu, Yupeng Li, Donghai Wen, Huoyou Long, Jinfeng Luo, Yubing Feng, Xiaoxi Zhuang, Fengxiang Zhang, Jianqi Liu, Fang Leng, Xingfen Lang, Yang Bai, Miaoqin She, Zhengchao Tu, Jingxuan Pan, Ke Ding